BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 35660972)

  • 21. Characteristics and long-term outcomes of advanced pleural mesothelioma in Latin America (MeSO-CLICaP).
    Rojas L; Cardona AF; Trejo-Rosales R; Zatarain-Barrón ZL; Ramírez-Tirado LA; Ruiz-Patiño A; Campos Gómez S; Corrales L; Oblitas G; Bacon L; Martín C; de Lima VCC; Freitas HC; Mas L; Vargas C; Carranza H; Otero J; Pérez MA; González L; Chirinos L; Granados ST; Rodriguez J; Báez R; Remolina Bonilla YA; Núñez Cerrillo G; Archila P; Cuello M; Karachaliou N; Rosell R; Arrieta O;
    Thorac Cancer; 2019 Mar; 10(3):508-518. PubMed ID: 30706690
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic significance of the lymphocyte-to-monocyte ratio in patients with malignant pleural mesothelioma.
    Yamagishi T; Fujimoto N; Nishi H; Miyamoto Y; Hara N; Asano M; Fuchimoto Y; Wada S; Kitamura K; Ozaki S; Kishimoto T
    Lung Cancer; 2015 Oct; 90(1):111-7. PubMed ID: 26259877
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low Merlin expression and high Survivin labeling index are indicators for poor prognosis in patients with malignant pleural mesothelioma.
    Meerang M; Bérard K; Friess M; Bitanihirwe BK; Soltermann A; Vrugt B; Felley-Bosco E; Bueno R; Richards WG; Seifert B; Stahel R; Weder W; Opitz I
    Mol Oncol; 2016 Oct; 10(8):1255-65. PubMed ID: 27378628
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disparities in Survival Due to Social Determinants of Health and Access to Treatment in US Patients With Operable Malignant Pleural Mesothelioma.
    Alnajar A; Kareff SA; Razi SS; Rao JS; De Lima Lopes G; Nguyen DM; Villamizar N; Rodriguez E
    JAMA Netw Open; 2023 Mar; 6(3):e234261. PubMed ID: 36951862
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Controlling Nutritional Status Score Is a Significant Independent Predictor of Poor Prognosis in Patients With Malignant Pleural Mesothelioma.
    Takamori S; Toyokawa G; Taguchi K; Edagawa M; Shimamatsu S; Toyozawa R; Nosaki K; Seto T; Hirai F; Yamaguchi M; Shoji F; Okamoto T; Takenoyama M; Ichinose Y
    Clin Lung Cancer; 2017 Jul; 18(4):e303-e313. PubMed ID: 28274690
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD70 expression correlates with a worse prognosis in malignant pleural mesothelioma patients via immune evasion and enhanced invasiveness.
    Inaguma S; Lasota J; Czapiewski P; Langfort R; Rys J; Szpor J; Waloszczyk P; Okoń K; Biernat W; Schrump DS; Hassan R; Kasai K; Miettinen M; Ikeda H
    J Pathol; 2020 Feb; 250(2):205-216. PubMed ID: 31639216
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy.
    Kao SC; Klebe S; Henderson DW; Reid G; Chatfield M; Armstrong NJ; Yan TD; Vardy J; Clarke S; van Zandwijk N; McCaughan B
    J Thorac Oncol; 2011 Nov; 6(11):1923-9. PubMed ID: 22011651
    [TBL] [Abstract][Full Text] [Related]  

  • 28. LAG3 is an independent prognostic biomarker and potential target for immune checkpoint inhibitors in malignant pleural mesothelioma: a retrospective study.
    Arimura K; Hiroshima K; Nagashima Y; Nakazawa T; Ogihara A; Orimo M; Sato Y; Katsura H; Kanzaki M; Kondo M; Tagaya E
    BMC Cancer; 2023 Dec; 23(1):1206. PubMed ID: 38062416
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The clinical utility of the LENT score in patients with malignant pleural mesothelioma.
    Söyler Y; Kavurgacı S; Gürel Akan E; Yılmaz Ü
    Tuberk Toraks; 2022 Dec; 70(4):341-348. PubMed ID: 36537091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: an individual patient pooled analysis of 10 European Organisation for Research and Treatment of Cancer Lung Cancer Group studies and an independent study validation.
    Hasan B; Greillier L; Pallis A; Menis J; Gaafar R; Sylvester R; Fennell DA; Baas P; Surmont V; Van Meerbeeck JP; O'brien ME
    Eur J Cancer; 2014 Nov; 50(16):2771-82. PubMed ID: 25155251
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inflammation-based prognostic indices in malignant pleural mesothelioma.
    Pinato DJ; Mauri FA; Ramakrishnan R; Wahab L; Lloyd T; Sharma R
    J Thorac Oncol; 2012 Mar; 7(3):587-94. PubMed ID: 22307011
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index.
    Kataoka Y; Yamamoto Y; Otsuki T; Shinomiya M; Terada T; Fukuma S; Yamazaki S; Hirabayashi M; Nakano T; Fukuhara S
    Jpn J Clin Oncol; 2015 Jun; 45(6):562-8. PubMed ID: 25838292
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.
    Zucali PA; Perrino M; Lorenzi E; Ceresoli GL; De Vincenzo F; Simonelli M; Gianoncelli L; De Sanctis R; Giordano L; Santoro A
    Lung Cancer; 2014 Jun; 84(3):265-70. PubMed ID: 24321581
    [TBL] [Abstract][Full Text] [Related]  

  • 34. External validation of prognostic indices for overall survival of malignant pleural mesothelioma.
    Kataoka Y; Yamamoto Y; Otsuki T; Kaku S; Maehashi-Wada N; Fukuma S; Hirabayashi M; Nakano T; Fukuhara S
    Lung Cancer; 2017 Nov; 113():88-92. PubMed ID: 29110856
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Computed tomography in the evaluation of malignant pleural mesothelioma-Association of tumor size to a sarcomatoid histology, a more advanced TNM stage and poor survival.
    Paajanen J; Laaksonen S; Ilonen I; Wolff H; Husgafvel-Pursiainen K; Kuosma E; Ollila H; Myllärniemi M; Vehmas T
    Lung Cancer; 2018 Feb; 116():73-79. PubMed ID: 29413055
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-Term Survival Outcomes of Cancer-Directed Surgery for Malignant Pleural Mesothelioma: Propensity Score Matching Analysis.
    Nelson DB; Rice DC; Niu J; Atay S; Vaporciyan AA; Antonoff M; Hofstetter WL; Walsh GL; Swisher SG; Roth JA; Tsao A; Gomez D; Giordano SH; Mehran R; Sepesi B
    J Clin Oncol; 2017 Oct; 35(29):3354-3362. PubMed ID: 28817374
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stratification of malignant pleural mesothelioma prognosis using recursive partitioning analysis.
    Suzuki H; Asami K; Hirashima T; Okamoto N; Yamadori T; Tamiya M; Morishita N; Shiroyama T; Takeoka S; Osa A; Azuma Y; Okishio K; Kawaguchi T; Atagi S; Kawase I
    Lung; 2014 Feb; 192(1):191-5. PubMed ID: 24141556
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survival results in biphasic malignant pleural mesothelioma patients: A multicentric analysis.
    Lococo F; Torricelli F; Lang-Lazdunski L; Veronesi G; Rena O; Paci M; Casadio C; Piana S; Novellis P; Di Stefano TS; Ciarrocchi A; Billè A
    J Thorac Cardiovasc Surg; 2020 Apr; 159(4):1584-1593.e2. PubMed ID: 31590954
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic factors and treatment outcomes of malignant pleural mesothelioma in Eastern Asian patients - A Taiwanese study.
    Wu TH; Lee LJ; Yuan CT; Chen TW; Yang JC
    J Formos Med Assoc; 2019 Jan; 118(1 Pt 2):230-236. PubMed ID: 29709339
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic values of preoperative C-reactive protein, albumin, and neutrophil ratios in patients with malignant pleural mesothelioma who underwent extrapleural pneumonectomy.
    Okita R; Okada M; Inokawa H; Murakami T; Ikeda E
    Surg Oncol; 2022 Aug; 43():101813. PubMed ID: 35816852
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.